Stocks Health care MAIA
NYSE · Health careMAIA Biotechnology, Inc. (MAIA)
It posted a net loss of $26.8M. At June 30, 2026 it held $0 in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 10, 2026.
Key facts about MAIA Biotechnology, Inc.
- Net worth
- MAIA Biotechnology, Inc. has a market value (market cap) of $66.3M at the latest share price, and shareholders' equity of $20.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2024 revenue was $0, with a net loss of $23.3M.
- Cash flow
- In fiscal 2025 operations used $18.8M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 10, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- MAIA Biotechnology, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
What MAIA Biotechnology, Inc. does
MAIA Biotechnology, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker MAIA.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$22.4M | -$0.70 | n/a |
| 2024 | $0 | -$23.3M | -$1.05 | n/a |
| 2023 | $0 | -$19.8M | -$1.49 | n/a |
| 2022 | $0 | -$16.2M | -$1.75 | n/a |
| 2022 | n/a | -$12.5M | -$2.37 | n/a |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What MAIA Biotechnology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- October 6, 2026
- September 25, 2026
- August 21, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 10, 2026
- May 22, 2026
- May 19, 2026Additional proxy material DEFA14A
- May 15, 2026Passive stake (5% or more) SCHEDULE 13G
- May 14, 2026
- May 11, 2026
Insider trades
What the people running MAIA Biotechnology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders bought $352.3K worth of shares on the open market in the last 90 days and sold none.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 14, 2026 | Vitoc VladChief Executive Officer, Director, 10% owner | Bought | 73,000 | $100K |
| September 10, 2026 | Guerrero RamiroDirector | Bought | 37,595 | $49.5K |
| August 28, 2026 | Guerrero RamiroDirector | Bought | 46,620 | $62.9K |
| August 27, 2026 | Guerrero RamiroDirector | Bought | 78,239 | $108.8K |
| August 26, 2026 | Guerrero RamiroDirector | Bought | 8,931 | $12.4K |
| August 24, 2026 | Guerrero RamiroDirector | Bought | 1,794 | $2.4K |
| August 20, 2026 | Guerrero RamiroDirector | Bought | 11,899 | $16.3K |
| June 1, 2026 | Gryaznov SergeiChief Scientific Officer | Bought | 2,000 | $2.7K |
Who owns MAIA
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| FGMK Business Holdings, LLC13G, passive with 1 related filers | 9.99% | March 3, 2025 |
| Vlad Vitoc13D, may seek influence | 9.66% | December 4, 2025 |
| Louie Ngar Yee13D, may seek influence | 6.5% | October 25, 2024 |
| The Stan V. Smith Trust Dated 199313D, may seek influence with 1 related filers | 6.32% | October 25, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 36 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Solas Capital Management, LLC | 3,030,845 | -1,266,159 |
| Alyeska Investment Group, L.P. | 2,500,000 | 0 |
| Vanguard Capital Management LLC | 2,413,270 | +339,225 |
| 683 Capital Management, LLC | 1,066,666 | 0 |
| Centric Wealth Management | 796,723 | 0 |
| Cable Car Capital, LP | 514,583 | -133,920 |
| Geode Capital Management, LLC | 504,380 | +143,899 |
| Bleichroeder LP | 500,000 | 0 |
| Renaissance Technologies LLC | 415,700 | new |
| BlackRock, Inc. | 403,011 | +275,033 |
| Vanguard Fiduciary Trust Co | 336,688 | +137,374 |
| State Street Corp | 201,750 | +62,800 |
| Bleakley Financial Group, LLC | 181,623 | new |
| Northern Trust Corp | 125,171 | +72,632 |
| Morgan Stanley | 104,017 | +90,158 |
| Bridgeway Capital Management, LLC | 76,000 | +40,000 |
| Two Sigma Investments, LP | 50,383 | new |
| Envestnet Asset Management Inc | 44,347 | new |
| Susquehanna International Group, Llp | 35,223 | new |
| Pvg Asset Management Corp | 34,135 | 0 |
Insiders
7 insiders reported holding 5,226,495 shares in total, about $5.7M at the last price.
| Holder | Shares |
|---|---|
| Smith StanDirector | 1,519,1781,519,178 held indirectly |
| Louie Ngar YeeDirector | 1,248,888 |
| Vitoc VladChief Executive Officer, Director, 10% owner | 1,049,121 |
| Guerrero RamiroDirector | 773,296 |
| Luput CristianDirector | 437,628 |
| Chaouki Steven MDirector | 151,873 |
| Gryaznov SergeiChief Scientific Officer | 46,511 |
Questions about MAIA
What does MAIA Biotechnology, Inc. do?
MAIA Biotechnology, Inc. is a company in the Health care sector, listed on NYSE as MAIA. Its shares trade on NYSE under the ticker MAIA.
What is MAIA Biotechnology, Inc.'s net worth?
MAIA Biotechnology, Inc. has a market value (market cap) of $66.3M at the latest share price, and shareholders' equity of $20.7M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is MAIA Biotechnology, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $26.8M.
When did MAIA Biotechnology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 10, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from October 6, 2026.
When is MAIA Biotechnology, Inc.'s next earnings report?
MAIA Biotechnology, Inc.'s next report was expected around November 9, 2026 and is not on file with the SEC yet.
Similar companies
Compare MAIA with
Follow MAIA
Get an email when MAIA Biotechnology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values MAIA Biotechnology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.